1、Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 1 6 November 2025 AstraZeneca results:9M and Q3 2025 Continued strong commercial performance and unprecedented pipeline delivery in the year to date Revenue and EPS summary 9M 2025%Change Q3 2025%

2、Change$m Actual CER1$m Actual CER -Product Sales 41,035 9 9 14,365 11 9 -Alliance Revenue 2,108 41 41 815 46 44 Product Revenue2 43,143 10 11 15,180 12 11 Collaboration Revenue 93 (14)(15)11 (81)(82)Total Revenue 43,236 10 11 15,191 12 10 Reported EPS($)5.10 43 42 1.64 77 70 Core3 EPS($)7.04 15 15 2

3、.38 14 12 Key performance elements for 9M 2025(Growth numbers at constant exchange rates)Total Revenue up 11%to$43,236m,driven by growth in all Therapy Areas,including 16%growth in Oncology and 13%growth in R&I Growth in Total Revenue across all major geographic regions Core Operating profit increas

4、ed 13%Core EPS increased 15%to$7.04 16 positive Phase III readouts and 31 approvals in major regions Pascal Soriot,Chief Executive Officer,AstraZeneca,said:“The strong underlying momentum across our business through the first nine months of the year sets us up well to sustain growth through 2026 and

5、 has us on track to deliver our 2030 ambition.Across our pipeline we have announced an unprecedented 16 positive Phase III trials this year,with four since our previous results including high-impact readouts for baxdrostat in hypertension and Enhertu and Datroway in breast cancer.We are also deliver

6、ing on our strategy to strengthen our operations in the United States to power our growth.This includes a historic agreement with the US government to lower the cost of medicines for American patients,and broadening our US manufacturing footprint having broken ground at our new$4.5bn Virginia manufa